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Background: Imidazoline I3 receptors (I-3R) can regulate insulin secretion in pancreatic β-cells. It has been indicated
that allantoin ameliorates hyperglycemia by activating imidazoline I2 receptors (I-2R). Thus, the effect of allantoin on
I-3R is identified in the present study.
Methods: We used male Wistar rats to screen allantoin’s ability for lowering of blood glucose and stimulation of
insulin secretion. Chinese hamster ovary-K1 cells transfected with imidazoline receptors (NISCH-CHO-K1 cells) were
also applied to characterize the direct effect of allantoin on this receptor. Additionally, KU14R as specific antagonist
was treated to block I-3R in rats and in the cultured pancreatic β-cells named Min 6 cells.
Results: In rats, allantoin decreased blood sugar with an increase in plasma insulin. Also, allantoin enhanced calcium
influx into NISCH-CHO-K1 cells in a way similar to agmatine, an I-R agonist. Moreover, KU14R dose-dependently
blocked allantoin-induced insulin secretion both in Min 6 cells and in Wistar rats.
Conclusion: Allantoin can activate I-3R to enhance insulin secretion for lowering of blood sugar in Wistar rats. Thus,
allantoin may provide beneficial effects as a supplement for diabetic patients after clinical trials.
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Allantoin is one of the active principles contained in
yam (Dioscorea spp.) [1]. Yam is widely used in the drug
industry, and Dioscorea rhizome contains ureides, in-
cluding allantoin, that prevent inflammation and ulcers
[2]. Herbs from Dioscoreaceae have been used to im-
prove diabetic disorders [3]. In Chinese traditional medi-
cine, Shan-Yaw (Dioscorea opposita) improves insulin
resistance [4], and the effect also observed in animals
[5]. Allantoin is contained in this herb [6], and we have
identified the plasma glucose- lowering action of allan-
toin in diabetic rats [7].
The antihyperglycemic action of allantoin in type-1-
like diabetic rats involves its activation of imidazoline
I-2 receptors (I-2Rs) [7]. Imidazoline receptors (I-Rs)
have many functions [8]. Due to the presence of agmatine
as endogenous ligand, the functions of I-Rs subtypes were
widely investigated: I-1 receptor is known to regulate blood
pressure [9]; I-3R mediates insulin secretion [10]; and I-2R* Correspondence: jtcheng5503@yahoo.com.tw
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unless otherwise stated.is mentioned to reduce blood glucose [11,12]. The I-R
expressed on pancreatic β-cells has been classified as I-3
site [13] showing different properties from the I-1 and/or
I-2 sites [14,15]. The insulin-secreting action of efaroxan,
an I-3R ligand, is mediated by calcium influx through the
closure of ATP-sensitive K+ (KATP) channel [16]. However,
the effect of allantoin on I-3R for insulin secretion is still
unknown.
Compounds with guanidine-like structures, including
metformin [17], can bind to I-Rs [8]. I-R activation pro-
motes glycemic control [18-20]. An increase in insulin
secretion via the activation of I-3R located in pancreatic
β-cells also seems helpful for glycemic control [21,22].
Allantoin has the ability to activate I-2R [7], but the effect
of allantoin on I-3R remained obscure. Thus, the present
study investigated whether allantoin can bind I-R and ex-
plored its effects on I-3R both in vivo and in vitro.Methods
Animals
The male Wistar rats weighing from 280 to 330 g were
purchased from the Animal Center of National Cheng. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cess to food and water in the house under a 12-h light/
dark cycle. The animal experiments were approved and
conducted in accordance with local institutional guide-
lines for the care and use of laboratory animals. All ex-
periments conformed to the Guide for the Care and Use
of Laboratory Animals as well as the guidelines of the
Animal Welfare Act.
The effect of allantoin on postprandial blood glucose
was performed as described previously [23]. The rats
were separated into three groups and eight animals in
each group. After fasting for 12 h, blood samples ob-
tained from tail vein were used to determine the plasma
glucose level at the basal level (0 min). Then, two groups
of animals received the injection of allantoin at 0.5 or
1 mg/kg into tail vein. Another group received a similar
injection of vehicle at same volume to use as the control.
At 30 min later, all rats received oral intake of glucose
solution (1 g/kg body weight). Blood samples were ob-
tained at desired time after the oral glucose challenge to
determine the plasma glucose level. The insulin level in
each sample was also estimated using an immunoassay
kit (Mercodia, Uppsala, Sweden).
Cell cultures
The Mus musculus insulinoma cell line Min 6 (BCRC
No. CRL-11506) and Chinese hamster ovary-K1 (CHO-K1)
cells (BCRC No. CCL-61) were purchased from the Culture
Collection and Research Center of the Food Industry
Institute (Hsin-Chiu City, Taiwan). Following a previous
method [24,25], Min 6 cells were maintained in RPMI
1640 medium, while CHO-K1 cells were maintained in
F-12 K medium supplemented with 10% fetal bovine
serum. The cells were sub-cultured once every three days
by trypsinization (Gibco), and the culture medium was
refreshed every 2–3 days.
Overexpression of NISCH in CHO-K1 cells
According to the previous report [26], CHO-K1 cells were
transiently transfected with human nischarin (NISCH)
gene, also known as human imidazoline receptor antisera-
selective (IRAS) protein, and an expression vector
(Origene, Rockville, MD, USA) using the TurboFect trans-
fection reagent (Thermo Fisher Scientific, USA). At 24 h
later, the transfected cells were used to treat with allantoin
or agmatine at indicated concentrations.
Measurement of insulin secretion
To identify the direct effect of allantoin on insulin secre-
tion, we used Min 6 cells to investigate the in vitro
secretion as described previously [27]. The Min 6 cells
were prepared at 1 × 105 cells per well in a 12-well plate
containing 1 ml of DMEM before the experiment. Then,
cells were incubated with KU14R (an I-3R antagonist)(Sigma-Aldrich, St. Louis, MO, USA) at effective con-
centrations or with same volume of vehicle, as the
control, for 30 min. All cells were treated with allan-
toin at the indicated concentrations for 1 h. After the
collection of media to store at −20°C, insulin levels in
the media were estimated using an immunoassay kit
(Mercodia).
Western blotting analysis
The cells were lysed with ice-cold lysis and the protein was
extracted following a previous report [3]. Then, each sam-
ple at 30 micrograms was separated by 10% sodium dode-
cylsulfate polyacrylamide gel electrophoresis. The blots
were then transferred to a polyvinyl difluoride membrane
(Millipore, Billerica, MA, USA). After blocking with
10% skim milk for 1 h, immunoblots were developed
with the primary antibody specific for NISCH and
DDK (Origene, Rockville, MD, USA). The blots were
subsequently hybridized using horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG (Calbiochem,
San Diego, CA, USA) and developed by a chemilu-
minescence kit (PerkinElmer). The optical densities
of the bands (37 kD) were identified through Gel-Pro
analyzer software 4.0 (Media Cybernetics, Silver Spring,
MD, USA).
Measurement of intracellular calcium
The intracellular calcium concentrations were deter-
mined using the fluorescent probe fura-2 as described in
our previous report [28]. In brief, the NISCH-CHO-K1
cells were placed in a buffered physiological saline solu-
tion (PSS) containing 5 mM fura-2. The cells were incu-
bated for 1 h under 5% CO2 in O2 aeration at 37.8°C.
After washing, the cells were incubated for another
30 min in PSS. The NISCH-CHO-K1 cells were inserted
into a temperature-controlled (37°C) cuvette containing
2 ml of PSS and indicated doses of allantoin or agmatine
for 1 h. The fluorescence was determined by a fluores-
cence spectrofluorometer (Hitachi F-2000). The intra-
cellular calcium [Ca2+]i was calculated from the ratio
R = F340/F380 by the following formula: [Ca2+]i = KdB
(R - Rmin)/(Rmax - R), where Kd is 225 nM, F is fluor-
escence, and B is the ratio of the fluorescence of the
free dye to that of the Ca2+-bound dye measured at
380 nm. Rmax and Rmin were determined in separate ex-
periments by using digoxin to equilibrate [Ca2+]i with am-
bient [Ca2+] (Rmax), and the addition of 0.1 mM MnCl2
and 1 mmol/L EGTA (Rmin). Background autofluores-
cence was measured in unloaded cells and was subtracted
from all measurements.
Changes of blood glucose and insulin in rats
KU14R (an I-3R antagonist) (Sigma-Aldrich, St. Louis,
MO, USA) at the effective dose (4 or 8 mg/kg) or
Figure 1 Effects of allantoin on insulin secretion and blood
glucose in Wistar rats. Plasma glucose was reduced by intravenous
(i.v.) injection of allantoin into fasted Wistar rats after glucose
(1 g/kg) loading (A). Basal plasma glucose (B) and basal plasma
insulin (C) were also influenced by allantoin. Values are indicated
as the mean and SEM from each group of eight rats. Vehicle only
(0.9% NaCl in distilled water) was given at the same volume. *P< 0.05,
**P < 0.01, and ***P < 0.001 versus data from animals treated with
vehicle (control).
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described previously [29,30] for 30 minutes before the
injection of allantoin (0.1, 1 or 2.5 mg/kg). Blood sam-
ples collected from the femoral vein at indicated times
were centrifuged and the plasma glucose was measured
in an automatic analyzer (Quik-Lab, Ames; Miles Inc.,
Elkhart, IN, USA). Plasma insulin was estimated from
each sample using an immunoassay kit (Mercodia,
Uppsala, Sweden).
Statistical analysis
Data are expressed as the mean ± SEM of each group.
Means of the two groups were compared by Student’s
t-test using the software Microsoft EXCEL. The dif-
ferences were analyzed by the unpaired t-test and consid-
ered significant at P < 0.05.
Results
Effect of allantoin on blood glucose in rats challenged
with glucose
We injected allantoin (0.5 or 1 mg/kg) into fasted Wistar
rats that received a glucose (1 g/kg) challenge to investi-
gate the effectiveness of allantoin. Allantoin produced a
marked reduction of hyperglycemia in these rats. This
action of allantoin was more effective at 1 mg/kg than
0.5 mg/kg (Figure 1A).
Effects of allantoin on insulin secretion and basal blood
glucose in rats
Normal Wistar rats were used to investigate the effects
of allantoin on insulin secretion and basal blood glucose.
The basal blood glucose was lowered by allantoin in a
dose-dependent manner (Figure 1B). Plasma insulin was
raised by allantoin in a same manner (Figure 1C). These
results show that allantoin may lower blood glucose
through an increase of plasma insulin.
Imidazoline receptor- mediated calcium influx in
transfected CHO-K1 cells
Transfection efficiency was confirmed through Western
blotting analysis. The over-expressed DDK and NISCH
genes were identified in these transfected NISCH-CHO-
K1 cells (Figure 2A and 2B). Additionally, calcium influx
was dose- dependently increased in NISCH-CHO-K1
cells treated with agmatine (Figure 2C), an I-R agonist.
The functional expression of NISCH in CHO-K1 cells
was confirmed.
Changes in calcium influx caused by allantoin in
NISCH-CHO-K1 cells
We tested the ability of allantoin to bind with imidazo-
line receptor. After incubation with allantoin, calcium
influx was significantly raised in NISCH-CHO-K1 cells,
similar to the increase stimulated by agmatine (Figure 2C).After comparison, allantoin induced calcium influx was
less effective than agmatine.
Comparison of the actions of allantoin and glibenclamide
in Min 6 cells
Glibenclamide has widely been used to stimulate insulin
secretion by increasing calcium influx and it was also
Figure 2 Allantoin induces calcium influx in CHO -cells transfected with imidazoline receptors. The expression of DDK (A) or NISCH (B)
was identified using Western blotting analysis. Changes in intracellular calcium by agmatine (open bar) or allantoin (gray bar) were detected
using the fura-2 probe by a fluorescence spectrofluorometer (C). All of the values are expressed as the mean ± SEM (n = 6 per group). *P < 0.05,
**P < 0.01 and ***P < 0.001 compared with the control group.
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glibenclamide significantly increased calcium influx at
the concentration of 1 μM. Allantoin (1 μM) increased
calcium influx to a level similar to that induced by 1 μM
glibenclamide (Figure 3A).
Effect of KU14R on the action of allantoin in Min 6 cells
The antagonist of I-3R, KU14R, influenced the action of
allantoin markedly (Figure 3B). Insulin secretion increased
by allantoin was inhibited by KU14R in a concentration-
dependent manner. At the highest concentration, KU14Rabolished the action of allantoin. This result indicates the
activation of I-3R by allantoin.
Effect of I-3R blockade by KU14R on the action of
allantoin in rats
The allantoin action in rats was also influenced by
KU14R. The increase in insulin secretion and the de-
crease in blood glucose caused by allantoin were both
markedly inhibited by KU14R (Figure 4) at the dose suf-
ficient to block I-3R [29,30]. Thus, the mediation of I-3R
in actions of allantoin was identified in vivo.
Figure 3 Characterization of allantoin induced actions in Min 6
cells. Changes in calcium influx by glibenclamide or allantoin were
determined in Min 6 cells (A). The effect of KU14R on allantoin
induced insulin secretion (B). All of the values are expressed as the
mean ± SEM (n = 6 per group). **P < 0.01 and ***P < 0.001 compared
with the control group.
Figure 4 Effects of I-3R blockade on allantoin-induced insulin
secretion and blood glucose reduction in Wistar rats. Data show
the effects of an I-3R antagonist (KU14R) on allantoin-induced blood
glucose reduction (A) and insulin secretion (B) in Wistar rats. Values
are expressed as the mean and SEM from each group of eight rats.
Vehicle (0.9% NaCl in distilled water) was given at the same volume.
*P < 0.05 and **P< 0.01 versus data from the vehicle-treated control.
Tsai et al. Nutrition & Metabolism 2014, 11:41 Page 5 of 7
http://www.nutritionandmetabolism.com/content/11/1/41Discussion
Yam containing allantoin is a widely used nutrient [2].
Allantoin ameliorates hyperglycemia in diabetic rats by
activating I-2R [7]. In the present study, we found that
allantoin also can activate I-3R, linking its increase of in-
sulin secretion to reduce blood glucose in Wistar rats.
Additionally, this is the first report demonstrated that
allantoin can activate I-R directly using the response in
CHO -cells transfected with imidazoline receptor gene
(NISCH-CHO-K1 cells). Moreover, we applied a pharma-
cological antagonist named KU14R at a dose sufficient to
block I-3R, as described previously [31,32], to block the ac-
tions of allantoin in both pancreatic β-cells (Min 6 cells)
and Wistar rats, indicating the mediation of I-3R in insulin
secretion induced by allantoin.
Allantoin is easily degraded in the intestinal tract [33]
and loses its activity after oral administration [34,35].
Thus, we treated rats with allantoin using intravenous
injection (iv). Allantoin (1 mg/kg, iv) attenuated the hyper-
glycemia in fasting rats challenged with glucose. Moreover,
allantoin decreased blood sugar and increased blood insu-
lin in normal rats in a dose-dependent manner. Thus,
bolus injection of allantoin induces lowering of bloodglucose in a way associated with the increased insulin
secretion in rats.
Imidazoline receptors have been established [36-38],
but research tools to study them are still not well devel-
oped. There is no ideal radioligand to perform ligand-
receptor binding assay. Also, the antagonist specific for
each subtype of imidazoline receptor is not sufficient. In
the present study, we transfected the imidazoline recep-
tor gene (NISCH) into CHO cells. Success of the trans-
fection was confirmed using Western blotting analysis.
Agmatine, a well-known ligand of I-Rs, induced an in-
crease in calcium influx in these cells, indicating that the
transfected CHO-cells were functional. Additionally, al-
lantoin enhanced calcium influx into NISCH- expressing
CHO-K1 cells in a manner similar to agmatine. The acti-
vation of imidazoline receptor by allantoin was thus con-
firmed. These results show that CHO -cells transfected
with imidazoline receptor gene can be used to identify
the direct effect of allantoin.
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to improve insulin sensitivity [39-42]. However, these re-
sults were observed in the absence of endogenous insu-
lin. We applied Min 6 cells to investigate the effect of
allantoin on I-3R in pancreatic cells and used glibencla-
mide as positive control. Glibenclamide has been applied
to enhance insulin secretion through an induction of
calcium influx in pancreatic β-cells [43,44]. We observed
that 1 μM allantoin increases calcium influx in Min 6
cells to a level similar to that produced by 1 μM gliben-
clamide. Glibenclamide is known to inhibit ATP-regulated
potassium (KATP) channels in pancreatic β-cells, thereby
causing calcium influx to result in the increase of intracel-
lular calcium [45]. In the present study, we identified that
allantoin increases calcium influx in pancreatic cells in a
manner similar to glibenclamide.
The binding site(s) of imidazolines in pancreatic β-cell
has been distinguished with I-1 and I-2 receptors [46].
I-1 sites were not expressed in β-cells and I-2 sites
were mentioned as not reliable for the activity of imi-
dazoline ligands [10]. Thus, imidazolines induced insu-
lin secretion after binding to a single site named I-3
site. In the present study, we found that an antagonist
specific for I-3R (KU14R) inhibited allantoin-induced
insulin secretion in Min 6 cells in a dose-dependent
manner. Similar results were observed in rats showing
the plasma insulin increasing action of allantoin blocked
by KU14R. Thus, activation of I-3R is involved in the insu-
lin secretion induced by allantoin.
Allantoin can activate I-1R in brain to produce antihy-
pertension [47] and decrease feeding behaviors [48].
Allantoin can stimulate I-2R to lower blood sugar and
improve insulin sensitivity in type 1-like diabetic rats
[39-42]. In this study, allantoin activates I-3R to increase
insulin secretion. Taken together, these findings indicate
that allantoin could be useful for treating metabolic
syndrome. However, more data are needed to confirm
this hypothesis, especially from the clinical trials, in the
future.Conclusion
Allantoin can enhance insulin secretion by activating
I-3R to lower blood glucose in rats. Thus, allantoin
or the related compound(s) that activates I-3R could
be developed for the supplementary treatment of diabetic
disorders.
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